Dynavax Technologies (DVAX)
(Delayed Data from NSDQ)
$11.19 USD
+0.04 (0.36%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.20 +0.01 (0.09%) 5:34 PM ET
4-Sell of 5 4
D Value D Growth NA Momentum NA VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DVAX 11.19 +0.04(0.36%)
Will DVAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVAX
Exelixis (EXEL) Beats Q2 Earnings Estimates
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
Other News for DVAX
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Dynavax Technologies Corp (DVAX) Announces Q2 2025 Financial Results Release and Conference ...
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, ...
Wolverine Asset Management LLC Increases Stake in Future Vision II Acquisition Corp
WOLVERINE ASSET MANAGEMENT LLC Increases Stake in Agriculture & Natural Solutions ...